Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Sanofi”

A Study to Evaluate the Effect of SAR443820 on Serum Neurofilament Levels in Male and Female Adult Participants With Multiple SclerosisTerminated
NCT05630547Phase 2Updated Oct 15, 2025
Sponsor: Sanofi
Multiple Sclerosis
Belgium, Bulgaria, Canada, Chile, China +5 more
A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.Active Not Recruiting
NCT06143891Phase 3Updated Oct 14, 2025
Sponsor: Sanofi
Chronic Graft Versus Host Disease
United States, Argentina, Australia, Austria, Belgium +19 more
Open Label Two-Arm Study to Evaluate Rilzabrutinib in IgG4-Related Disease ParticipantsCompleted
NCT04520451Phase 2Updated Oct 14, 2025
Sponsor: Principia Biopharma, a Sanofi Company
Immunoglobulin G4 Related Disease
United States, Canada, France, Italy, Spain
Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and InfantsTerminated
NCT04825223Phase 1Updated Oct 10, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
Meningococcal Immunisation · Healthy Volunteers
United States, Puerto Rico
Study of a Single Intramuscular Dose of Nirsevimab in the Prevention of Hospitalizations Due to Respiratory Syncytial Virus (RSV) Infection in Healthy Term and Preterm Infants During the First Year of LifeCompleted
NCT05437510Phase 3Updated Oct 9, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
RSV Immunization · Healthy Volunteer
France, Germany, United Kingdom
Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (pSjS)Completed
NCT04572841Phase 2Updated Oct 9, 2025
Sponsor: Sanofi
Sjögren's Syndrome · Sjogren's Syndrome
United States, Argentina, Belgium, Canada, Chile +7 more
Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and AdolescentsActive Not Recruiting
NCT06838000Phase 3Updated Oct 6, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
Pneumococcal Infections
United States, Estonia, Poland, Thailand
To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid CancerCompleted
NCT01496313Phase 4Updated Oct 3, 2025
Sponsor: Sanofi
Thyroid Cancer
United States, Czechia, India, Israel, Italy +4 more
A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia AActive Not Recruiting
NCT05911763N/AUpdated Oct 2, 2025
Sponsor: Sanofi
Hemophilia A
United States
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)Terminated
NCT04914897Phase 2Updated Oct 2, 2025
Sponsor: Sanofi
Pleural Mesothelioma · Non-small Cell Lung Cancer
United States, Argentina, Australia, Chile, France +6 more
A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A in TaiwanRecruiting
NCT06684314N/AUpdated Oct 2, 2025
Sponsor: Sanofi
Hemophilia A
Taiwan
Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid TumorsTerminated
NCT04659603Phase 2Updated Oct 1, 2025
Sponsor: Sanofi
Breast Cancer Metastatic · Pancreatic Carcinoma Metastatic
United States, Argentina, Chile, Hungary, Netherlands +5 more
High Dose Inspiratory Muscle Training in LOPDCompleted
NCT05431127NAUpdated Oct 1, 2025
Sponsor: Duke University
Late-Onset Pompe Disease · Lysosomal Disease
United States
Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple SclerosisActive Not Recruiting
NCT04879628Phase 2Updated Sep 30, 2025
Sponsor: Sanofi
Multiple Sclerosis
United States, Bulgaria, Canada, Czechia, France +5 more
Brigham and Women's Rheumatoid Arthritis Sequential StudyActive Not Recruiting
NCT01793103N/AUpdated Sep 26, 2025
Sponsor: Brigham and Women's Hospital
Rheumatoid Arthritis
United States
Dupilumab in Chinese Adult Participants With CRSwNPCompleted
NCT05878093Phase 3Updated Sep 25, 2025
Sponsor: Sanofi
Chronic Rhinosinusitis With Nasal Polyps
China
A Study to Assess the Effect of Oral Belumosudil on Inhibition of Various Proteins in the Fed State in Healthy Male SubjectsCompleted
NCT05806567Phase 1Updated Sep 25, 2025
Sponsor: Kadmon, a Sanofi Company
Immune System Disorder · Healthy Volunteers
United States
A Study to Investigate Safety, Tolerability and Clinical Response With SAR441566 Compared With Placebo in Participants With Mild to Moderate PsoriasisCompleted
NCT05453942Phase 1Updated Sep 25, 2025
Sponsor: Sanofi
Psoriasis
Germany
To Assess the Pharmacokinetics and Safety and Tolerability of Efanesoctocog Alfa (BIVV001)in Adults With Type 2N and 3 Von Willebrand Disease (VWD)Completed
NCT04770935Phase 1Updated Sep 25, 2025
Sponsor: Bioverativ, a Sanofi company
Von Willebrand's Disease (VWD)
United States, France
Study to Determine Absorption, Metabolism, and Excretion of [14C]-SAR439859, and to Assess Absolute Oral Bioavailability of Amcenestrant (SAR439859), in Healthy Post-menopausal WomenCompleted
NCT04940026Phase 1Updated Sep 24, 2025
Sponsor: Sanofi
Breast Cancer · Healthy Volunteers
United Kingdom
Sarilumab COVID-19Completed
NCT04327388Phase 3Updated Sep 24, 2025
Sponsor: Sanofi
Corona Virus Infection
Argentina, Brazil, Canada, Chile, France +6 more
iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)Completed
NCT05413369Phase 3Updated Sep 24, 2025
Sponsor: Sanofi
Type 2 Diabetes Mellitus
China
Evaluation of the Relationship Between ABCG2 Mutation and Teriflunomide Exposure and Safety in Chinese RMS Patients Treated With Teriflunomide 14 mg Once Daily for 24 WeeksCompleted
NCT04410965Phase 4Updated Sep 24, 2025
Sponsor: Sanofi
Multiple Sclerosis
China
Study on Two Adjuvanted Dose Levels of Panblok H7+MF59 Compared for Immunogenicity and Safety With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and OlderCompleted
NCT05608005Phase 1, Phase 2Updated Sep 24, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
Influenza · Healthy Volunteers
United States
Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Taiwanese Adults 65 Years of Age and OlderCompleted
NCT04537234Phase 3Updated Sep 24, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
Influenza (Healthy Volunteers)
Taiwan

Previous page Next page